Lars L. Karlsson

Lars L. Karlsson

Auto-generated profile, based on publicly available information

Lars L. Karlsson

Karolinska Institutet

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2012 in Planetary and Space Science
Verified
Journal Article
Closed access
DLDag Linnarsson
Dag Linnarsson
JCJames Carpenter
James Carpenter
BFBice Fubini
Bice Fubini
PGPer Gerde
Per Gerde
LKLars L. Karlsson
Lars L. Karlsson
WWWim van Westrenen
Wim van Westrenen

1 January 2015 in Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
DLDag Linnarsson
Dag Linnarsson
RHRichard L. Hughson
Richard L. Hughson
KFKatelyn S. Fraser
Katelyn S. Fraser
GCGilles Clément
Gilles Clément
LKLars L. Karlsson
Lars L. Karlsson
JZJochen Zange
Jochen Zange
Exposure to artificial gravity (AG) in a short-arm centrifuge has potential benefits for maintaining human performance during long-term space missions. Eleven subjects were investigated during three campaigns of 5 days head-down bed rest: 1) bed rest without countermeasures (control), 2) bed rest and 30 min of AG (AG1) daily, and 3) bed rest and six periods of 5 min AG (AG2) daily. During centrifugation, the supine subjects were exposed to AG in the head-to-feet direction with 1 G at the center of mass. Subjects participated in the three campaigns in random order. The cardiovascular effects of bed rest and countermeasures were determined from changes in tolerance to a head-up tilt test with superimposed lower body negative pressure (HUT), from changes in plasma volume (PV) and from changes in maximum aerobic power (V̇o2peak) during upright work on a cycle ergometer. Complete data sets were obtained in eight subjects. After bed rest, HUT tolerance times were 36, 64, and 78% of pre-bed rest baseline during control, AG1 and AG2, respectively, with a significant difference between AG2 and control. PV and V̇o2peakdecreased to 85 and 95% of pre-bed rest baseline, respectively, with no differences between the treatments. It was concluded that the AG2 countermeasure should be further investigated during future long-term bed rest studies, especially as it was better tolerated than AG1. The superior effect of AG2 on orthostatic tolerance could not be related to concomitant changes in PV or aerobic power.

1 October 2009 in Respiratory Physiology & Neurobiology
Verified
Journal Article
Closed access
LKLars L. Karlsson
Lars L. Karlsson
SBS. Lesley Blogg
S. Lesley Blogg
PLPeter Lindholm
Peter Lindholm
MGMikael Gennser
Mikael Gennser
THTryggve Hemmingsson
Tryggve Hemmingsson
DLDag Linnarsson
Dag Linnarsson

1 November 2009 in Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
LKLars L. Karlsson
Lars L. Karlsson
YKYannick Kerckx
Yannick Kerckx
LGLars E. Gustafsson
Lars E. Gustafsson
THTryggve E. Hemmingsson
Tryggve E. Hemmingsson
DLDag Linnarsson
Dag Linnarsson
Inhalation of toxic dust during planetary space missions may cause airway inflammation, which can be monitored with exhaled nitric oxide (NO). Gravity will differ from earth, and we hypothesized that gravity changes would influence exhaled NO by altering lung diffusing capacity and alveolar uptake of NO. Five subjects were studied during microgravity aboard the International Space Station, and 10 subjects were studied during hypergravity in a human centrifuge. Exhaled NO concentrations were measured during flows of 50 (all gravity conditions), 100, 200, and 500 ml/s (hypergravity). During microgravity, exhaled NO fell from a ground control value of 12.3 ± 4.7 parts/billion (mean ± SD) to 6.6 ± 4.4 parts/billion (P = 0.016). In the centrifuge experiments and at the same flow, exhaled NO values were 16.0 ± 4.3, 19.5 ± 5.1, and 18.6 ± 4.7 parts/billion at one, two, and three times normal gravity, where exhaled NO in hypergravity was significantly elevated compared with normal gravity (P ≤ 0.011 for all flows). Estimated alveolar NO was 2.3 ± 1.1 parts/billion in normal gravity and increased significantly to 3.9 ± 1.4 and 3.8 ± 0.8 parts/billion at two and three times normal gravity (P < 0.002). The findings of decreased exhaled NO in microgravity and increased exhaled and estimated alveolar NO values in hypergravity suggest that gravity-induced changes in alveolar-to-lung capillary gas transfer modify exhaled NO.

30 March 2017 in World Customs Journal
Verified
Journal Article
Open access
PDF file
LKLars Karlsson
Lars Karlsson
This paper presents recent changes in the area of compliance management and identifies how the Authorised Economic Operator (AEO) instrument is about to transform into more mature and developed models. This will allow the AEO concept to become the future game changer it was originally intended to become, for both international trade and other stakeholders in the global supply chain.

1 December 2013 in Respiratory Physiology & Neurobiology
Verified
Journal Article
Closed access
MAM. Ax
M. Ax
LKL.L. Karlsson
L.L. Karlsson
ASAlejandro Sanchez-Crespo
Alejandro Sanchez-Crespo
SLS.G.E. Lindahl
S.G.E. Lindahl
DLD. Linnarsson
D. Linnarsson
JPJ. Petersson
J. Petersson